d="p0010">Respiratory disease continues to be a major cause of morbidity and mortality in DMD.
dd><dt class="label">•dt><dd>d="p0015">In phase 3 DELOS trial idebenone significantly reduced respiratory function loss.
dd><dt class="label">•dt><dd>d="p0020">Patients on idebenone experienced fewer bronchopulmonary adverse events.
dd><dt class="label">•dt><dd>d="p0025">Patients on idebenone reported less use of systemic antibiotics.
dd><dt class="label">•dt><dd>d="p0030">Use of idebenone in DMD results in clinically relevant outcome.
dd>dl>